{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:41:55Z","timestamp":1772664115271,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12883-017-0844-z","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T16:21:49Z","timestamp":1490631709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment"],"prefix":"10.1186","volume":"17","author":[{"given":"Tjalf","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Scarlet","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Landsman-Blumberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Kempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Glei\u00dfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"issue":"12","key":"844_CR1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.apmr.2007.07.032","volume":"88","author":"J Paltamaa","year":"2007","unstructured":"Paltamaa J, Sarasoja T, Leskinen E, Wikstrom J, Malkia E. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil. 2007;88(12):1649\u201357.","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"844_CR2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/14656566.2011.586338","volume":"12","author":"H Panitch","year":"2011","unstructured":"Panitch H, Applebee A. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opin Pharmacother. 2011;12(10):1511\u201321.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"844_CR3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s12325-009-0082-x","volume":"26","author":"HL Zwibel","year":"2009","unstructured":"Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043\u201357.","journal-title":"Adv Ther"},{"issue":"2","key":"844_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.17925\/ENR.2011.06.02.115","volume":"6","author":"P Asch Van","year":"2011","unstructured":"Van Asch P. Impact of mobility impairment in multiple sclerosis 2-patients\u2019 perspectives. Eur Neurol Rev. 2011;6(2):115\u201320.","journal-title":"Eur Neurol Rev"},{"issue":"3","key":"844_CR5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","volume":"4","author":"NG Larocca","year":"2011","unstructured":"Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4(3):189\u2013201.","journal-title":"Patient"},{"key":"844_CR6","unstructured":"EPAR summary for the public - Fampyra (fampridine) - EMA\/430040\/2011, EMEA\/H\/C\/002097 [ http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002097\/WC500109958.pdf ]. Accessed 1 July 2016."},{"issue":"1","key":"844_CR7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25(1):106\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"844_CR8","volume-title":"Diagnose und therapie der multiplen sklerose","author":"Deutsche Gesellschaft f\u00fcr Neurologie (German Neurological Society)","year":"2014","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (German Neurological Society). Diagnose und therapie der multiplen sklerose. 2014. Leitlinie S2e. AWMF-Registernummer: 030\/050 2014."},{"key":"844_CR9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1472-6963-14-381","volume":"14","author":"A Hoer","year":"2014","unstructured":"Hoer A, Schiffhorst G, Zimmermann A, Fischaleck J, Gehrmann L, Ahrens H, Carl G, Sigel KO, Osowski U, Klein M, et al. Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system. BMC Health Serv Res. 2014;14:381.","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"844_CR10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.clinthera.2013.07.330","volume":"35","author":"MM Bonafede","year":"2013","unstructured":"Bonafede MM, Johnson BH, Wenten M, Watson C. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Clin Ther. 2013;35(10):1501\u201312.","journal-title":"Clin Ther"},{"key":"844_CR11","unstructured":"Consumer Price Index and Inflation Rate. [ https:\/\/www.destatis.de\/EN\/FactsFigures\/NationalEconomyEnvironment\/Prices\/ConsumerPriceIndices\/ConsumerPriceIndices.html ]."},{"issue":"7","key":"844_CR12","first-page":"113","volume":"105","author":"P Flachenecker","year":"2008","unstructured":"Flachenecker P, Stuke K, Elias W, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Zettl UK, Rieckmann P. Multiple sclerosis registry in Germany: results of the extension phase 2005\/2006. Dtsch Arztebl Int. 2008;105(7):113\u20139.","journal-title":"Dtsch Arztebl Int"},{"key":"844_CR13","first-page":"1","volume":"11","author":"M Jara","year":"2015","unstructured":"Jara M, Sidovar MF, Henney HR. Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Ther Clin Risk Manag. 2015;11:1\u20137.","journal-title":"Ther Clin Risk Manag"},{"key":"844_CR14","unstructured":"Zusammenfassende Dokumentation \u00fcber die \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V - Fampridin, Stand: 28. November 2012 [ https:\/\/www.g-ba.de\/informationen\/nutzenbewertung\/14\/#tab\/beschluesse ]."},{"key":"844_CR15","unstructured":"Anlage III - Vorlage zur Abgabe einer schriftlichen Stellungnahme zur Nutzenbewertung nach \u00a7 35a SGB V Stellungnahme Arzneimittelkommission Fampridine Vergleichstherapie, 23.05.2012 [ http:\/\/www.akdae.de\/Stellungnahmen\/AMNOG\/A-Z\/Fampridin\/Fampridin.pdf ]. Accessed 1 July 2016."},{"issue":"1","key":"844_CR16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.18553\/jmcp.2007.13.1.44","volume":"13","author":"JD Prescott","year":"2007","unstructured":"Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44\u201352.","journal-title":"J Manag Care Pharm"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-017-0844-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T22:53:14Z","timestamp":1658875994000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-017-0844-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1186\/s12883-017-0844-z","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,27]]},"article-number":"62"}}